[illegible]

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

([illegible])

(Stock Code: 02196)

2013 THIRD QUARTERLY REPORT

T[illegible] Rule 13.09(2) [illegible] Rule 13.10B [illegible] Rule [illegible] G[illegible] L[illegible] S[illegible] T[illegible] S[illegible] E[illegible] H[illegible] K[illegible] L[illegible] I[illegible] I[illegible] Pr[illegible] P[illegible] I[illegible] A[illegible] S[illegible] F[illegible] Or[illegible] (C[illegible] 571 [illegible] L[illegible] H[illegible] K[illegible]).

T[illegible] 2013 [illegible] S[illegible] F[illegible] P[illegible] (Gr[illegible]) C[illegible]., L[illegible].* (“**Company**”, [illegible] “**Group**”). T[illegible] PRC A[illegible] S[illegible] B[illegible] E[illegible].

B[illegible] Or[illegible] B[illegible]
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
C[illegible]

S[illegible], P[illegible]'[illegible] R[illegible] C[illegible]
30 O[illegible]b[illegible]r 2013

[illegible]

* [illegible]

§1 IMPORTANT NOTICE

1.1 T b r r r C , r r , r r r rr r r l r , l r r l r ll l ll r b l r r l , r l r .

1.2 All D r r C B r .

1.3 C Q , C r C , H J , C F l O r J , D r r A D r (A O r) l l r rr r l l l r r ◆ r rl r r .

1.4 T l r ◆ r rl r r Gr b .

§2 MAJOR FINANCIAL INFORMATION OF THE GROUP AND CHANGES IN SHAREHOLDERS OF THE COMPANY

2.1 M r l r

A r , r r r m m :

: Crr : RMB

Items	The Reporting Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period	Description
G rl rm l -rr	10,251,236.77	596,825,644.44	
G rm b l l rr r , l l rl r r b C m r m r rm l l r	2,878,850.90	13,168,079.40	
G l rl l lbl l rr , m rl rm l l lbl l rr lbl - r- l l , r rm rl C m ' r r r b	80,220,837.82	218,571,999.35	M l l lbl - r- l l l r l l r r Gr r R r r
O r - r m r r m	462,524.66	–1,915,596.10	
E m	–23,279,225.73	–195,412,839.05	
I m r r (r)	–7,678,145.29	–13,090,843.51	
T l	62,856,079.13	618,146,444.53	

2.2 T l mb r r l r , r l T 10 r l r T 10 r r r l r C m r r r

: S r

T l mb r r l r					111,905
The shareholding status of the Top 10 shareholders					
Name of the shareholder	**Capacity**	**Shareholding (%)**	**Total number of shares held**	**Number of restricted shares held**	**Number of shares pledged or frozen**
S F H T l (Gr) C ., L .	D m - l l	41.09	920,641,314	0	N
HKSCC NOMINEES LIMITED *(o e)*	O r l l	14.96	335,255,500	0	
C L I r C ., L . — D -P r l D — 005L — FH002 S		1.69	37,868,964	0	N
C C r B — H A H L S S r I m F		1.44	32,188,808	0	N
I r l C mm r l B C — H T F C L F S S r I m F		0.95	21,318,308	0	N
I r l C mm r l B C — J S Gr ll l bl - S S r I m F		0.85	19,120,000	0	N
C M r B C ., L . — E rBr B D S r r All S S r I m F		0.81	18,110,252	0	N
N l S l S r F 104 r l		0.74	16,599,805	0	N
B C mm — P H C 50 O - S r I m F		0.46	10,199,839	0	N
B C mm — A S S r I m F		0.45	10,000,000	0	N

The Top 10 unrestricted shareholders of tradable shares		
Name of the shareholder (in full)	**Number of unrestricted tradable shares held at the end of the reporting period**	**Type and number of shares**
S F H T l (Gr) C ., L .	920,641,314	RMB r r r
HKSCC NOMINEES LIMITED (No e)	335,255,500	O r l r r
C L I r C ., L . — D — P r l D — 005L — FH002 S	37,868,964	RMB r r r
C C r B — H A H L S S r I F	32,188,808	RMB r r r
I r l C r l B C — H T F C L F S S r I F	21,318,308	RMB r r r
I r l C r l B C — J S Gr ll l bl - S S r I F	19,120,000	RMB r r r
C M r B C ., L . — E rBr B D S r r All S S r I F	18,110,252	RMB r r r
N l S l S r F 104 r l	16,599,805	RMB r r r
B C — P H C 50 O - S r I F	10,199,839	RMB r r r
B C — A S S r I F	10,000,000	RMB r r r
D r r l r l r r b r l r	T r I r l C r l B C — H T F C L F S S r I F I r l C r l B C — J S Gr ll l bl - S S r I F r b I r l C r l B C L ; T r B C — P H C 50 O - S r I F B C — A S r r b B C C ., L .; T r C C r B — H A H L S S r I F B C — A S r r b H A F M C ., L .; T r N l S l S r F 104 r l B C — P H C 50 O - S r I F r b P F M C ., L .; T	

§3 SIGNIFICANT EVENTS

3.1 S m r l m m l r Gr r r

√A l bl □N A l bl

: C rr : RMB

Balance Sheet				
Items	**Closing balance as at the end of the Period**	**Opening balance as at the beginning of the Year**	**Ratio of change**	**Reasons**
C l	2,485,783,000.50	4,972,524,758.70	–50%	M l r m r m r r r r r 2013
Tr r bl	1,316,781,579.78	907,307,576.06	45%	M l l l r m l l m r r r r r 2013
I r r bl	7,615,057.77	17,674,707.55	–57%	M l r r r r r r r r 2013
I bl	2,368,367,750.12	1,752,799,860.87	35%	M l l r r r r r 2013
D l m r	42,946,124.18	29,475,413.33	46%	M l r R&D m r r r r r 2013
G ll	2,710,407,586.05	1,661,770,763.96	63%	M l l r r r r r 2013
O r - rr	236,069,350.21	100,654,101.39	135%	M l r r l r m m, r m r r m l r r r r r 2013
D rr m	72,033,067.63	31,482,514.80	129%	M l l r r r r r 2013
S r - rm l	1,199,559,074.08	519,422,250.00	131%	M l r r - rm b r r r r r 2013
D bl	12,240,519.57	4,725,748.28	159%	M l m r l bl m r r l r r r r r r 2013
O r rr l b l	33,196,473.53	526,384,431.15	–94%	M l m r - rm b r r r r r 2013

Income Statement				
Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Ratio of change	Reasons
[illegible]	7,070,780,938.31	5,387,845,935.96	31%	[illegible] 2013
[illegible]	3,957,631,876.59	3,005,217,397.09	32%	[illegible] 2013
[illegible] (“–” [illegible])	39,511,717.28	–14,636,854.56	N/A	[illegible] 2013
[illegible]	313,206,671.22	202,061,631.73	55%	[illegible] 2013
[illegible]	72,257,721.95	33,558,889.22	115%	[illegible] 2013
[illegible]	285,252,496.15	–436,322,994.17	N/A	[illegible] 2013

Statement of Cash Flow				
Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)	Ratio of change	Reasons
[illegible]	–1,757,461,995.58	–368,977,652.38	376%	[illegible] 2013

3.2 [illegible]

√ [illegible] □ [illegible]

[illegible] 26 [illegible] 2013, [illegible] 2013 [illegible] 25 [illegible] 2013, [illegible] CSRC [illegible] (2013) No. 774). [illegible] CSRC, [illegible] 2013 [illegible]

S r r C , r r R r S r I S (r r) S F P r l (Gr) C ., L .*. T b S r I S (r r) b r l r' r l r l .

3.3 F l ll r b C , r l r r ll r

☐A l bl √N A l bl

3.4 r l l l r r r r b r r r r r l l r r r r r r

☐A l bl √N A l bl

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

L l r r : **Chen Qiyu**

30 O b r 2013

§4 APPENDICES

4.1 Consolidated balance sheet

30 e e e 2013

Pr . . r b : **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

. : . r . C r rr : RMB T . . r . : . r .

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C . . 6 . l	2,485,783,000.50	4,972,524,758.70
S l m r r		
L . b r r . . l . .		
F . . l . l r r .	258,756,754.96	224,834,307.14
B ll r . bl	293,416,923.81	306,710,161.00
Tr r . bl	1,316,781,579.78	907,307,576.06
Pr . m	279,681,295.65	239,307,192.55
Pr m m r . bl		
R . r . r . bl		
R . r r r r r . bl		
I r r . bl	7,615,057.77	17,674,707.55
D . r . bl	15,697,156.84	12,298,837.25
O r r . bl	467,158,390.71	423,080,420.35
P r . ll b . . l		
I r	1,629,432,467.70	1,273,438,729.51
N - rr . r		
O r rr .	4,495,956.06	4,341,123.93
T . l rr	6,758,818,583.78	8,381,517,814.04
Non-current assets:		
Pr . r l . . .		
A . l bl - r- . l . . l .	1,665,410,046.04	1,454,122,878.62
H l - -m r . m		
L - rm r . bl		
L - rm 6 . m	9,668,859,344.13	8,593,169,673.95
I m . r r .		
F .	2,987,437,844.46	2,595,295,851.85
C r . . r r	1,055,727,109.86	881,963,019.236.9( )-.2(

Consolidated balance sheet (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Non-current assets (Continued):		
D rr	72,033,067.63	31,482,514.80
O r - rr	236,069,350.21	100,654,101.39
T l - rr	20,830,762,112.56	17,125,622,651.97
T l		

Consolidated balance sheet (Continued)

30 June 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Equity attributable to the owners (or equity attributable to shareholders):		
Paid-in capital (or share capital)	2,240,462,364.00	2,240,462,364.00
Capital reserve	4,396,998,107.25	4,287,287,930.01
Less: treasury shares		
Special reserve		
Surplus reserve	1,338,476,598.49	1,338,476,598.49
General risk reserve		
Undistributed profits	6,621,610,997.36	5,703,028,462.15
Foreign currency translation difference	–4,289,492.31	–10,462,767.38
Total equity attributable to owners of the Parent company	14,593,258,574.79	13,558,792,587.27
Minority interests	1,889,445,595.04	1,745,855,848.86
Total equity attributable to owners	16,482,704,169.83	15,304,648,436.13
Total liabilities and equity attributable to owners	27,589,580,696.34	25,507,140,466.01

Legal Representative: Chen Qiyu   Chief Financial Officer: [illegible]   Director of Accounting Department: [illegible]

Balance sheet of the Parent Company

30 e e e 2013

Pr r b : **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

: C rr : RMB T :

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
C ϕ l	967,810,425.06	2,804,108,583.37
F l l r r		
B ll r bl		
Tr r bl		
Pr m		
I r r bl	112,185,785.22	98,972,778.68
D r bl	24,240,000.00	
O r r bl	1,207,151,982.57	941,562,545.17
I r	517,042.01	516,409.53
N - rr r		
O r rr	280,000,000.00	250,000,000.00
T l rr	2,591,905,234.86	4,095,160,316.75
Non-current assets:		
A l bl - r- l l		
H l - -m r m		
L - rm r bl		
L - rm ϕ m	5,471,340,934.74	4,173,763,622.82
I m r r		
F	20,153,012.47	20,815,349.96
C r r r		
Pr l		
D l		
Pr b l l		
O l		
I bl	3,215,662.67	3,496,198.41
D l m r		
G ll		
L - rm rr r		
D rr m		
O r - rr	4,470,831,299.40	4,035,133,683.09
T l - rr	9,965,540,909.28	8,233,208,854.28
T l	12,557,446,144.14	12,328,369,171.03

Balance sheet of the Parent Company (Continued)

30 e e e 2013

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
S r- rm l		
F l l b l l r r		
B ll bl		
Tr bl		
R		
bl	26,138,331.81	29,108,232.08
T bl	16,833,088.84	5,188,721.77
I r bl	155,509,208.37	152,405,396.96
D bl		
O r bl	554,584,851.12	46,800,203.98
N - rr l b l r	360,000,000.00	355,000,000.00
O r rr l b l		499,375,000.00
T l rr l b l	1,113,065,480.14	1,087,877,554.79
Non-current liabilities:		
L - rm l	125,000,000.00	165,000,000.00
B bl	4,070,832,033.25	4,063,347,254.54
L - rm bl		
S bl		
A r l b l		
D rr m l b l		
O r - rr l b l	2,275,000.00	2,500,000.00
T l - rr l b l	4,198,107,033.25	4,230,847,254.54
T l l b l	5,311,172,513.39	5,318,724,809.33
Equity attributable to the owners (or equity attributable to shareholders):		
P - l (r r l)	2,240,462,364.00	2,240,462,364.00
C l r r	3,754,014,307.53	3,755,009,519.04
L : r r r		
S r r		
S r l r r	305,635,420.68	305,635,420.68
G r l r r		
r r r	946,161,538.54	708,537,057.98
T l rb bl r (r rb bl r l r)	7,246,273,630.75	7,009,644,361.70
T l l b l rb bl r (r rb bl r l r)	12,557,446,144.14	12,328,369,171.03

L l R r C F l O r: D r r A
C m : C Q H J D r m : J

4.2 **Consolidated Income Statement**

d. a — e e e 2013

Pr . r b : **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

. : . , C rr : RMB T . , . : , .

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. T . l . r . r .	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
I l : O r . r .	2,561,491,585.94	1,893,571,781.13	7,070,780,938.31	5,387,845,935.96
I r .				
E r . r .				
F .				
II. T . l . r .	2,386,286,775.10	1,788,349,054.26	6,624,840,911.15	5,169,344,744.07
I l : O r .	1,443,380,576.18	1,070,386,676.04	3,957,631,876.59	3,005,217,397.09
I r .				
F .				
Pr . r .				
C . ,				
N . r . r r . r r				
P l .				
A r r r . r				
B . r . r	17,703,464.04	15,513,271.83	53,354,062.65	45,680,204.73
S ll .	479,445,326.56	378,562,373.30	1,365,131,254.39	1,095,194,687.55
A . r .	348,227,860.44	233,150,221.33	953,270,651.18	737,364,358.43
F .	96,141,071.35	89,160,189.77	284,390,085.53	276,468,676.31
A . r l	1,388,476.53	1,576,321.99	11,062,980.81	9,419,419.96
Pl : G r . r l (“–” . l)	–548,949.75	–4,627,534.57	39,511,717.28	–14,636,854.56
I . (“–” . l)	290,003,715.25	421,463,463.75	1,383,399,844.53	1,287,581,764.07
I l : G r . . . r	201,434,469.70	198,347,616.50	581,668,523.72	576,814,622.40
F r . (“–” . l)				
III. O r . r (“–” . l)	464,659,576.34	522,058,656.05	1,868,851,588.97	1,491,446,101.40
Pl : N - r . r .	19,388,740.32	10,990,516.89	72,257,721.95	33,558,889.22
L : N - r .	1,260,832.39	1,998,060.21	7,231,879.03	6,724,472.72
I l : L . l - rr .	260,198.27	–243,201.72	979,886.77	946,040.98

Income Statement of the Parent Company

d ɴ a — e e e 2013

Pr r b : **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

: C rr : RMB T :

Items	Current Amount (Jul – Sep)	Amount of the Last Period (Jul – Sep)	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. O r r				
L : O r				
B r r				
S ll				
A r	25,499,951.01	17,552,163.07	82,756,689.01	80,257,596.41
F	17,330,429.70	20,109,120.09	27,772,618.27	53,461,091.55
A r l				
Pl : G r r l (“–” l)				
I (“–” l)	8,229,013.36	242,785,000.00	820,929,379.59	459,475,631.89
I l : G r r	6,268,813.36	2,665,000.00	1,839,063.36	27,355,631.89
II. O r r (“–” l)	–34,601,367.35	205,123,716.84	710,400,072.31	325,756,943.93
Pl : N - r r	76,900.00	234,093.38	236,049.11	734,093.38
L : N - r		–570,000.00	2,514,544.42	860,000.00
I l : L l - rr			5,725.77	
III. T l r (“–” l l)	–34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
L : I				
I . N r (“–” l)	–34,524,467.35	205,927,810.22	708,121,577.00	325,631,037.31
. E r r r :				
(1) b r r r				
(2) l r r r				
I. O r r			51,779.40	27,699,470.25
II. T l r	–34,524,467.35	205,927,810.22	708,173,356.40	353,330,507.56

L l R r C : C Q

C F l O r: H J

D r r A D r : J

4.3 Consolidated Statement of Cash Flow

dn a – e e e 2013

Consolidated Statement of Cash Flow (Continued)

[illegible] 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
II. Cash flow generated from investing activities (Continued):		
C [illegible]	711,664,658.89	839,693,736.40
C [illegible]	251,949,461.45	734,761,521.45
N [illegible]		
N [illegible]	2,011,879,515.78	
O [illegible]	100,020,349.23	9,072,797.31
S [illegible]	3,075,513,985.35	1,583,528,055.16
N [illegible]	–1,757,461,995.58	–368,977,652.38
III. Cash flow generated from financing activities:		
C [illegible]	2,088,710.98	761,199.00
I [illegible]	2,088,710.98	761,199.00
C [illegible]	1,302,361,982.24	1,022,152,808.76
C [illegible]		1,486,950,000.00
O [illegible]	329,448,475.13	262,541,891.46
S [illegible]	1,633,899,168.35	2,772,405,899.22
C [illegible]	1,221,891,677.53	2,628,044,486.20
C [illegible]	950,844,046.86	601,916,917.03
I [illegible]	702,264,204.84	366,813,171.49
O [illegible]	48,488,630.70	101,408,014.93
S [illegible]	2,221,224,355.09	3,331,369,418.16
N [illegible]	–587,325,186.74	–558,963,518.94
IV. Effects of exchange rate fluctuations on cash and cash equivalents	–25,426,268.76	–4,569,909.53
V. Net increase of cash and cash equivalents	–1,902,809,425.34	–517,020,589.16
Pl[illegible]: O [illegible]	4,171,574,742.12	2,428,219,484.36
VI. Closing balance of cash and cash equivalents	2,268,765,316.78	1,911,198,895.20

L[illegible] R[illegible]: C[illegible] Q[illegible]   C[illegible] F[illegible] O[illegible]: H[illegible] J[illegible]   D[illegible] A[illegible]: [illegible] J[illegible]

Statement of Cash Flow of the Parent Company

dn a – e e e 2013

Pr r b : **Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

: C rr : RMB T :

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
I. Cash flow generated from operating activities:		
C r rm l r r r		
R l		
O r r rl r	37,439,681.37	40,008,504.21
Sb- l l rm r	37,439,681.37	40,008,504.21
C r r r r		
C r b m l	47,805,533.82	43,283,375.23
T l	20,609,862.43	11,891,537.59
O r rl r	31,711,001.63	44,174,769.12
Sb- l l rm r	100,126,397.88	99,349,681.94
N l r rm r	–62,686,716.51	–59,341,177.73
II. Cash flow generated from investing activities:		
C r rm m	.6(r -392.6(8(	)-387.)6.9 73-2646.2)6.9,90

Statement of Cash Flow of the Parent Company (Continued)

đn. a – e e e 2013

Items	From the beginning of the year to the end of the Reporting Period (Jan – Sep)	From the beginning of the previous year to the end of the Reporting Period of the previous year (Jan – Sep)
III. Cash flow generated from financing activities:		
C r r l rb		
C r r b rr	255,115,078.77	
C r r b		1,486,950,000.00
O r r rl	1,904,031,173.98	4,295,169,165.49
Sb- l l r	2,159,146,252.75	5,782,119,165.49
C r b l	790,115,078.77	454,000,000.00
C r rb r r r	674,744,025.09	302,177,196.32
O r rl	2,109,471,293.35	5,478,222,986.00
Sb- l l r	3,574,330,397.21	6,234,400,182.32
N l r r	–1,415,184,144.46	–452,281,016.83
IV. Effects of exchange rate fluctuations on cash and cash equivalents	–22,851,531.32	
V. Net increase of cash and cash equivalents	–1,198,160,658.31	–9,857,758.83
Pl : O b l l	2,090,971,083.37	155,005,881.32
VI. Closing balance of cash and cash equivalents	892,810,425.06	145,148,122.49

L l R r C F l O r: D r r A
C : C Q H J D r : J